Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sebastiaan J. Hullegie is active.

Publication


Featured researches published by Sebastiaan J. Hullegie.


Open Forum Infectious Diseases | 2015

Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control Study

Joost W. Vanhommerig; Femke A.E. Lambers; Janke Schinkel; Ronald B. Geskus; Joop E. Arends; Thijs J.W. van de Laar; Fanny N. Lauw; Kees Brinkman; Luuk Gras; Bart J. A. Rijnders; Jan T. M. van der Meer; Maria Prins; J. T. M. Van Der Meer; Richard Molenkamp; M. Mutschelknauss; Hans-Erik Nobel; H.W. Reesink; J. Schinkel; M. van der Valk; G.E.L. van den Berk; David Kwa; N. van der Meche; A. Toonen; D. Vos; M. van Broekhuizen; Jan Mulder; J.E. Arends; A. van Kessel; I. de Kroon; Andre Boonstra

Background. Since 2000, incidence of sexually acquired hepatitis C virus (HCV)-infection has increased among human immunodeficiency virus (HIV)-infected men who have sex with men (MSM). To date, few case-control and cohort studies evaluating HCV transmission risk factors were conducted in this population, and most of these studies were initially designed to study HIV-related risk behavior and characteristics. Methods. From 2009 onwards, HIV-infected MSM with acute HCV infection and controls (HIV-monoinfected MSM) were prospectively included in the MOSAIC (MSM Observational Study of Acute Infection with hepatitis C) study at 5 large HIV outpatient clinics in the Netherlands. Written questionnaires were administered, covering sociodemographics, bloodborne risk factors for HCV infection, sexual behavior, and drug use. Clinical data were acquired through linkage with databases from the Dutch HIV Monitoring Foundation. For this study, determinants of HCV acquisition collected at the inclusion visit were analyzed using logistic regression. Results. Two hundred thirteen HIV-infected MSM (82 MSM with acute HCV infection and 131 MSM without) were included with a median age of 45.7 years (interquartile range [IQR], 41.0–52.2). Receptive unprotected anal intercourse (adjusted odds ratio [aOR], 5.01; 95% confidence interval [CI], 1.63–15.4), sharing sex toys (aOR, 3.62; 95% CI, 1.04–12.5), unprotected fisting (aOR, 2.57; 95% CI, 1.02–6.44), injecting drugs (aOR, 15.62; 95% CI, 1.27–192.6), sharing straws when snorting drugs (aOR, 3.40; 95% CI, 1.39–8.32), lower CD4 cell count (aOR, 1.75 per cubic root; 95% CI, 1.19–2.58), and recent diagnosis of ulcerative sexually transmitted infection (aOR, 4.82; 95% CI, 1.60–14.53) had significant effects on HCV acquisition. Conclusions. In this study, both sexual behavior and biological factors appear to independently increase the risk of HCV acquisition among HIV-infected MSM.


PLOS ONE | 2016

Frequencies of circulating MAIT cells are diminished in chronic hCV, HIV and HCV/ HIV Co-Infection and do not recover during therapy

Michelle Spaan; Sebastiaan J. Hullegie; B. Beudeker; Kim Kreefft; Gertine W. van Oord; Zwier M. A. Groothuismink; Marjolein van Tilborg; Bart J. A. Rijnders; Robert J. de Knegt; Mark A.A. Claassen; Andre Boonstra

Objective Mucosal-associated invariant T (MAIT) cells comprise a subpopulation of T cells that can be activated by bacterial products and cytokines to produce IFN-γ. Since little is known on MAIT cells during HCV infection, we compared their phenotype and function in comparison to HIV and HCV/HIV co-infected patients, and determined the effect of IFN-α-based and direct-acting antiviral therapy on MAIT cells of HCV patients. Methods Blood samples from patients with chronic HCV (CHCV), virologically suppressed HIV, acute HCV/HIV co-infection (AHCV/HIV) and healthy individuals were examined by flowcytometry for phenotype and function of MAIT and NK cells. Results and Conclusions Compared to healthy individuals, the frequency of CD161+Vα7.2+ MAIT cells was significantly decreased in patients with CHCV, HIV and AHCV/HIV co-infection. CD38 expression on MAIT cells was increased in AHCV/HIV patients. MAIT cells were responsive to IFN-α in vitro as evidenced by enhanced frequencies of IFN-γ producing cells. IFN-α-based therapy for CHCV decreased the frequency of IFN-γ+ MAIT cells, which was still observed 24 weeks after successful therapy. Importantly, even after successful IFN-α-based as well as IFN-α-free therapy for CHCV, decreased frequencies of MAIT cells persisted. We show that the frequencies of MAIT cells are reduced in blood of patients with CHCV, HIV and in AHCV/HIV co-infection compared to healthy individuals. Successful therapy for CHCV did not normalize MAIT cell frequencies at 24 weeks follow up. The impact of HIV and HCV infection on the numbers and function of MAIT cells warrant further studies on the impact of viral infections and the antimicrobial function of MAIT cells.


Clinical Infectious Diseases | 2018

Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy

Anne Boerekamps; Guido E.L. van den Berk; Lauw N Fanny; Eliane M. S. Leyten; Marjo van Kasteren; Arne van Eeden; D. Posthouwer; Mark A.A. Claassen; Anton S Dofferhoff; Dominique W M Verhagen; Wouter F. W. Bierman; Kamilla D. Lettinga; Frank P. Kroon; Corine E. Delsing; Paul H. P. Groeneveld; Robert Soetekouw; Edgar J.G. Peters; Sebastiaan J. Hullegie; Stephanie Popping; David A. M. C. van de Vijver; Charles A. Boucher; Joop E. Arends; Bart J. A. Rijnders

Background Direct-acting antivirals (DAAa) cure hepatitis C virus (HCV) infections in 95% of infected patients. Modeling studies predict that universal HCV treatment will lead to a decrease in the incidence of new infections but real-life data are lacking. The incidence of HCV among Dutch human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) has been high for >10 years. In 2015 DAAs became available to all Dutch HCV patients and resulted in a rapid treatment uptake in HIV-positive MSM. We assessed whether this uptake was followed by a decrease in the incidence of HCV infections. Methods Two prospective studies of treatment for acute HCV infection enrolled patients in 17 Dutch HIV centers, having 76% of the total HIV-positive MSM population in care in the Netherlands. Patients were recruited in 2014 and 2016, the years before and after unrestricted DAA availability. We compared the HCV incidence in both years. Results The incidence of acute HCV infection decreased from 93 infections during 8290 person-years of follow-up (PYFU) in 2014 (11.2/1000 PYFU; 95% confidence interval [CI], 9.1-13.7) to 49 during 8961 PYFU in 2016 (5.5/1000 PYFU; 4.1-7.2). The incidence rate ratio of 2016 compared with 2014 was 0.49 (95% CI, .35-.69). Simultaneously, a significant increase in the percentage positive syphilis (+2.2%) and gonorrhea (+2.8%) tests in HIV-positive MSM was observed at sexual health clinics across the Netherlands and contradicts a decrease in risk behavior as an alternative explanation. Conclusions Unrestricted DAA availability in the Netherlands was followed by a 51% decrease in acute HCV infections among HIV-positive MSM.


Journal of Hepatology | 2016

Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients

Sebastiaan J. Hullegie; Mark A.A. Claassen; Guido E.L. van den Berk; Jan T. M. van der Meer; D. Posthouwer; Fanny N. Lauw; Eliane M. S. Leyten; Peter P. Koopmans; C. Richter; Arne van Eeden; Wouter F. W. Bierman; Astrid M. Newsum; Joop E. Arends; Bart J. A. Rijnders

BACKGROUND & AIMS Acute hepatitis C virus infections (AHCV) are prevalent among HIV positive men having sex with men and generally treated with pegylated interferon-alpha (PegIFN) and ribavirin (RBV) during 24weeks. The addition of a protease inhibitor could shorten therapy without loss of efficacy. METHODS We performed an open-label, single arm study to investigate the efficacy and safety of a 12-week course of boceprevir, PegIFN and RBV for AHCV genotype 1 infections in 10 Dutch HIV treatment centers. The primary endpoint of the study was achievement of sustained virological response rate at week 12 (SVR12) in patients reaching a rapid viral response at week 4 (RVR4) and SVR12 in the intent to treat (ITT) entire study population was the most relevant secondary endpoint. RESULTS One hundred twenty-seven AHCV patients were screened in 16 months, of which 65 AHCV genotype 1 patients were included. After spontaneous clearance in six patients and withdrawal before treatment initiation in two, 57 started therapy within 26 weeks after infection. RVR4 rate was 72%. SVR12 rate was 100% in the RVR4 group. SVR12 rate in the ITT group was 86% and comparable to the SVR12 rate of 84% in 73 historical controls treated for 24 weeks with PegIFN and RBV in the same study centers. CONCLUSION With the addition of boceprevir to PegIFN and RBV, treatment duration of AHCV genotype 1 can be reduced to 12 weeks without loss of efficacy. Given the high drug costs and limited availability of interferon-free regimens, boceprevir PegIFN and RBV can be a considered a valid treatment option for AHCV. ClinicalTrials.gov, number NCT01912495.


Clinical Microbiology and Infection | 2015

Current knowledge and future perspectives on acute hepatitis C infection

Sebastiaan J. Hullegie; Joop E. Arends; Bart J. A. Rijnders; William L. Irving; D. Salmon; M. Prins; A.M. Wensing; Paul Klenerman; Hakan Leblebicioglu; Christoph Boesecke; Jürgen K. Rockstroh; Andy I. M. Hoepelman

Acute hepatitis C virus (HCV) infections are frequently seen worldwide in certain risk groups, with an annual incidence rate varying between 0.08% and 66%. Although this incidence is substantial, a delayed diagnosis during chronic infection is most often made in the absence of clinical symptoms in the acute phase of the infection. Currently used methods to diagnose acute HCV infection are IgG antibody seroconversion and repeated HCV RNA measurements, although no definitive diagnostic test is currently available. Progress in the field of adaptive and innate immune responses has aided both advances in the field of HCV vaccine development and a more basic understanding of viral persistence. The rapid changes in the treatment of chronic HCV infection will affect therapeutic regimens for acute HCV infection in the coming years, leading to shorter treatment courses and pegylated interferon-free modalities. This review gives an overview of the current knowledge and uncertainties, together with some future perspectives on acute hepatitis C epidemiology, virology, immunology, and treatment.


Clinical Microbiology and Infection | 2016

Acute hepatitis C in the Netherlands: characteristics of the epidemic in 2014

Sebastiaan J. Hullegie; G. van den Berk; Eliane M. S. Leyten; Joop E. Arends; Fanny N. Lauw; J. T. M. Van Der Meer; D. Posthouwer; A. van Eeden; P.P. Koopmans ; C. Richter; M.E.E. van Kasteren; Frank P. Kroon; Wouter F. W. Bierman; Php Groeneveld; Kamilla D. Lettinga; R. Soetekouw; Edgar J.G. Peters; D. W. M. Verhagen; A.I. van Sighem; Mark A.A. Claassen; Bart J. A. Rijnders

Within the Dutch Acute HCV in HIV Study, a surveillance system was initiated to estimate the incidence of hepatitis C virus (HCV) infections in 2014. Following the Dutch HIV treatment guidelines, HIV-positive men having sex with men (MSM) in 19 participating centers were screened. Ninety-nine acute HCV infections were reported, which resulted in a mean incidence of 11 per 1000 patient-years of follow-up. Unfortunately, the HCV epidemic among Dutch HIV-positive MSM is not coming to a halt.


Journal of the International AIDS Society | 2017

HCV antigen instead of RNA testing to diagnose acute HCV in patients treated in the Dutch Acute HCV in HIV Study

Sebastiaan J. Hullegie; Corine H. GeurtsvanKessel; Annemiek A. van der Eijk; Chris Ramakers; Bart J. A. Rijnders

Introduction: Affordable and sensitive screening methods for acute hepatitis C (HCV) are necessary to successfully intervene in the current HCV epidemic among HIV‐positive men having sex with men. HCV core antigen (Ag) testing has been proven effective in diagnosing chronic HCV‐infected patients at low costs. We studied the characteristics of HCV Ag testing in acute HCV‐infected HIV‐positive patients.


Clinical Microbiology and Infection | 2017

Use of whole genome sequencing in the Dutch Acute HCV in HIV study: focus on transmitted antiviral resistance

Mette T. Christiansen; Sebastiaan J. Hullegie; Martin Schutten; Katja Einer-Jensen; Helena Tutill; Judith Breuer; Bart J. A. Rijnders

OBJECTIVE Within HIV-positive men having sex with men, the epidemic of hepatitis C virus (HCV) is ongoing. Transmission of resistant variants of HCV after failure of treatment with directly acting antivirals (DAA) could be a major threat to the effectivity of therapy. We determined whether HCV-resistant variants to DAAs were prevalent amongst patients with an acute HCV infection diagnosed in 2013 and 2014 in the Netherlands. METHODS Target enrichment for viral nucleic acid separation and deep sequencing were used to recover whole HCV genomes of 50 patients with an acute HCV infection. The genomes were assembled by de novo assembly and analysed for known DAA resistance mutations. RESULTS In acute HCV infected treatment-naive patients, the relevant resistance-associated substitutions were Q80K (40%) in NS3/4a, M28V (24%) and Q30H combined with Y93H (2%) in NS5A and M414T (2%) or S556G (2%) in NS5b. Patients whose HCV infection failed to respond to boceprevir, peginterferon and ribavirin therapy developed mutations in NS3 at position T54A and R155K. CONCLUSIONS Target enrichment and whole genome sequencing were successfully applied directly on clinical samples from patients with an acute HCV infection.


Clinical Microbiology and Infection | 2015

Current knowledge and future perspectives on acute hepatitis C

Sebastiaan J. Hullegie; Joop E. Arends; Bart J. A. Rijnders; William L. Irving; Dominique Salmon; M. Prins; A.M. Wensing; Paul Klenerman; Hakan Leblebicioglu; Christoph Boesecke; Jürgen K. Rockstroh; Andy I. M. Hoepelman

Acute hepatitis C virus (HCV) infections are frequently seen worldwide in certain risk groups, with an annual incidence rate varying between 0.08% and 66%. Although this incidence is substantial, a delayed diagnosis during chronic infection is most often made in the absence of clinical symptoms in the acute phase of the infection. Currently used methods to diagnose acute HCV infection are IgG antibody seroconversion and repeated HCV RNA measurements, although no definitive diagnostic test is currently available. Progress in the field of adaptive and innate immune responses has aided both advances in the field of HCV vaccine development and a more basic understanding of viral persistence. The rapid changes in the treatment of chronic HCV infection will affect therapeutic regimens for acute HCV infection in the coming years, leading to shorter treatment courses and pegylated interferon-free modalities. This review gives an overview of the current knowledge and uncertainties, together with some future perspectives on acute hepatitis C epidemiology, virology, immunology, and treatment.


Journal of General Virology | 2017

Decreased pro-inflammatory immune responses during recurrent acute HCV infections in HIV co-infected patients

Sebastiaan J. Hullegie; Joop E. Arends; Zwier M. A. Groothuismink; Suzan D. Pas; Bart J. A. Rijnders; Andre Boonstra; Mark A.A. Claassen

Patients in high-risk groups continue to transmit the hepatitis C virus (HCV) and frequently experience reinfections. Since little is known regarding the immune response to HCV during reinfection, we compared primary and consecutive acute HCV infections in patients with an HIV infection, and focused on the cytokine bridging innate to adaptive immunity. We observed that the serum levels of IL-12p40, MIP-1β, MIG and IP-10 increased during primary acute HCV infection, but not during subsequent secondary acute reinfections. The weaker pro-inflammatory cytokine responses observed during HCV reinfections suggest more limited secondary acute immune responses, which may prevent damage to the infected liver.

Collaboration


Dive into the Sebastiaan J. Hullegie's collaboration.

Top Co-Authors

Avatar

Bart J. A. Rijnders

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mark A.A. Claassen

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eliane M. S. Leyten

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Wouter F. W. Bierman

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

C. Richter

Erasmus University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

William L. Irving

Nottingham University Hospitals NHS Trust

View shared research outputs
Researchain Logo
Decentralizing Knowledge